Biopsy Devices Market Trends Adoption of Image Guided and Minimally Invasive Diagnostic Solutions

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biopsy Devices Market- (By Product Type (Needle Biopsy Devices (Guidance Systems, Biopsy Consoles, Site Markers, Biopsy Guns (Automated Systems, Semi-Automated Systems), Needles), Skin Biopsy Devices (Punch Biopsy Instruments, Shave Biopsy Instruments), Consumables (Forceps, Trocars, Trays, Other Consumables), By Biopsy Type (Tissue Biopsy (Needle Biopsy, Surgical Biopsy, Skin Biopsy), Liquid Biopsy), By Anatomy (Breast, Lung, Bone, Liver, Uterus/Cervix, Abdomen, Prostate, Cardiac, Skin, Others), By Disease Type (Cancer, Infections, Autoimmune Disorders, Non-Cancerous Indications, Others), By Guidance Technique (Growth-Share Analysis, Ultrasound-Guided Biopsy, X-Ray-Guided Biopsy, MRI-Guided Biopsy, CT-Guided Biopsy)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Biopsy Devices Market is valued at USD 6.84 Bn in 2023, and it is expected to reach US$ 20.04 Bn by 2031, with a CAGR of 14.51% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2228

A biopsy is a fundamental diagnostic procedure that involves the collection of tissue samples to identify and evaluate a range of medical conditions, most notably cancer. When malignancy is suspected, tissue specimens are obtained and subjected to detailed pathological analysis to support accurate diagnosis and treatment planning. A variety of biopsy techniques are utilized in clinical practice, including skin biopsy, vacuum-assisted biopsy, incisional and excisional biopsy, fine-needle aspiration, core needle biopsy, and shave biopsy.

The rising global prevalence of cancer-including high-incidence conditions such as breast, prostate, and lung cancer-has substantially increased demand for advanced diagnostic and therapeutic interventions. This trend has also contributed to greater awareness of screening and diagnostic procedures among patients and healthcare providers. Continuous technological innovation in biopsy techniques, including three-dimensional optical biopsy, MRI-guided targeting, and ultrasound-assisted systems, has significantly improved diagnostic accuracy and procedural efficiency.

In parallel, the growing emphasis on early detection of chronic and life-threatening diseases is accelerating the adoption of advanced biopsy technologies, such as stereotactic-guided systems. The expanding range of clinical applications for biopsy devices is expected to support sustained market growth over the forecast period.

List of Prominent Players in the Biopsy Devices Market:
• Argon Medical Devices, Inc.
• B. Braun SE
• Becton
• Dickinson and Company
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Group Incorporated
• Conmed Corporation
• FUJIFILM Holdings Corporation
• GE Healthcare
• Inrad, Inc.
• Medtronic plc
• Olympus Corporation
• Siemens Healthineers AG
• Stryker Corporation
• Zamar Care
• Changzhou Jiuhong Medical Instrument Co., Ltd.
• Kindly (KDL) Meditech
• Ningbo Xinwell Medical Technology Co., LTD.
• Shenzhen Manners Technology Co., Ltd.
• Zhejiang Soudon Medical Technology Co., Ltd
• Agilent Technologies, Inc.
• BGI Group
• Biocept, Inc.
• Bio-Rad Laboratories, Inc.
• Dxcover Limited
• Elypta Limited
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Micronoma
• QIAGEN
• Revvity, Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The biopsy device market is experiencing steady growth, supported by advancements in medical technology, evolving regulatory environments, and the rising global prevalence of chronic diseases. One of the most influential growth drivers is the increasing incidence of cancer worldwide, which has heightened the need for accurate and timely diagnostic solutions. As cancer remains a leading cause of morbidity and mortality, early detection has become a clinical priority, directly reinforcing demand for biopsy procedures and associated devices. Growing awareness of cancer screening programs and improvements in diagnostic accuracy are further strengthening market momentum.

Challenges:
Despite favorable growth prospects, the market faces several constraints. The high acquisition and maintenance costs of advanced biopsy systems can limit adoption, particularly in budget-sensitive healthcare settings. In addition, procedural complexities associated with certain biopsy techniques, such as core needle biopsies, and heightened concerns regarding screening-related risks may restrict broader utilization. The inherently invasive nature of biopsy procedures, which involves tissue removal, also carries the potential for post-procedural complications, including infection, thereby raising safety considerations that may impact market expansion.

Regional Trends:
North America is expected to maintain its leading position in the global biopsy device market, supported by a mature healthcare infrastructure, a high concentration of skilled medical professionals, and the presence of major industry participants. The region is projected to achieve sustained growth over the forecast period. Meanwhile, the Asia-Pacific region is anticipated to witness accelerated market expansion, driven by demographic shifts such as a growing elderly population, rising disposable incomes, and increasing awareness of preventive healthcare and disease screening initiatives. The higher incidence of cancer among aging populations across the region is likely to further stimulate demand, positioning Asia-Pacific as a key growth market for biopsy devices.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2228

Recent Developments:
• In Sept 2023, A revolutionary collaboration has been declared between Roche France, Foundation Medicine, and the Institute Gustave Roussy to provide cancer patients in France with in-house liquid biopsy genomic testing. By transferring FoundationOne®Liquid CDx technology to the Institute Gustave Roussy, Roche France and Foundation Medicine have the potential to provide liquid biopsy testing for comprehensive genomic profiling (CGP) in all patients in France diagnosed with advanced cancer.
• In August 2022, Mammotome announced the release of the Mammotome DualCoreTM biopsy system, the company's first twin-stage core biopsy tool. This novel core biopsy device adds to the Mammotome ultrasound-guided breast biopsy portfolio, which already includes the Mammotome® Elite Tetherless Vacuum-Assisted Biopsy Device (tetherless VABB) and the Mammotome RevolveTM Dual Vacuum-Assisted Breast Biopsy System (tethered VABB).

Segmentation of Biopsy Devices Market-
By Product Type-
• Needle Biopsy Devices
o Guidance Systems
o Biopsy Consoles
o Site Markers
o Biopsy Guns
 Automated Systems
 Semi-Automated Systems
o Needles
• Skin Biopsy Devices
o Punch Biopsy Instruments
o Shave Biopsy Instruments
• Consumables
o Forceps
o Trocars
o Trays
o Other Consumables
By Biopsy Type
• Tissue Biopsy
o Needle Biopsy
o Surgical Biopsy
o Skin Biopsy
• Liquid Biopsy
By Anatomy-
• Breast
• Lung
• Bone
• Liver
• Uterus/Cervix
• Abdomen
• Prostate
• Cardiac
• Skin
• Others
By Disease Type-
• Cancer
• Infections
• Autoimmune Disorders
• Non-Cancerous Indications
• Others
By Guidance Technique -
• Growth-Share Analysis
• Ultrasound-Guided Biopsy
• X-Ray-Guided Biopsy
• MRI-Guided Biopsy
• CT-Guided Biopsy
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/biopsy-devices-market/2228

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.